Reagent Kit for Determining Fibrinolytic Activity of Human Blood Plasma (XIIa-Dependent Fibrinolysis) according to TU 9398-280-05595541-2007. Intended for investigating the fibrinolysis system using a manual method.
The study of fibrinolytic activity of blood plasma allows for assessing the state of internal and external mechanisms of plasminogen activation, plasmin formation, and fibrin clot lysis. The method is sensitive to various pathologies in plasma proteolytic systems and is applied in combination with other methods.
Principle of Operation: The test is based on measuring the time of complete lysis of the euglobulin fraction obtained from blood plasma when precipitated in an acidic environment and containing blood coagulation factors and fibrinolysis. The euglobulin fraction, containing plasminogen, fibrinogen, coagulation factors, and lacking fibrinolysis inhibitors, is isolated from the blood plasma. Upon adding calcium chloride to this fraction, a fibrin clot forms, which is subsequently lysed by plasmin. The reaction is activated by factor XIIa. The time from the formation of the clot to its dissolution reflects the fibrinolytic activity of the investigated blood plasma.
Kit Composition: • Concentrated imidazole buffer (2 ml/vial) – 1 vial; • 0.025 M calcium chloride solution (10 ml/vial) – 2 vials; • 1% acetic acid solution (10 ml/vial) – 1 vial; • 0.5% kaolin suspension (5 ml/vial) – 2 vials.
One kit is intended for conducting 40 analyses.
Results Interpretation: In the normal range, complete lysis of the euglobulin fraction occurs within 5-12 minutes.
Activation of fibrinolysis in the body occurs in heterotransfusion shock, peptone shock, burns, electrotrauma, during epileptic seizures, and in patients awaiting surgical intervention. Shortening of the euglobulin fraction lysis time (fibrinolysis activation process) indicates a decrease in the concentration of fibrinogen – hypo- and dysfibrinogenemia.
Reduced fibrinolytic activity of blood is one of the leading factors in thrombus formation and atherosclerosis, especially in patients with thromboembolic complications. Prolonged lysis time of the euglobulin fraction (inhibition of fibrinolysis process) indicates the first phase of DIC syndrome and hyperfibrinogenemia.
Normal and pathological values of XIIa-dependent fibrinolysis should be monitored using Control Plasma (pool of healthy donors) Plasma H, code KM-1.
